Inhibikase Therapeutics, Inc.

NASDAQ:IKT

Biotechnology

Healthcare
$1.38 +3.57%

+$0.06 today

Market cap
$193.57M
Beta
0.97
P/E (TTM)
-3.4
EPS (TTM)
-$0.52
52W Low $1.33High $2.26

Volume 0.43M

Average 1.03M

IKT Interest Income

Income earned on cash, deposits, and investments held by the company.

Inhibikase Therapeutics, Inc.NASDAQ: IKT

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income grows, but more slowly than its trailing trend

Q1 FY2026 interest income of $1.46M rose 58.9% year over year, behind the +129.4% change in trailing-twelve-month interest income. Sequentially, it rose 40.4% from the prior quarter. Over 3 fiscal years it compounded at +268.2% a year.

Context

  • Interest income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +58.9% toward the trailing-twelve-month pace of +129.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.46M+40.4% QoQ
Last fiscal yearDec 2025
$3.72M+247.5% YoY
LTMMar 2026
$4.26M+129.4% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+58.9%——
1 year+247.5%——
3-year CAGR+268.2%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
3.72M USD
Year-over-year change
+247.5%
4-year CAGR
+269.5%

Interest Income vs competitors

How IKT compares with its peers on the latest reported figures

  • IKT's LTM Mar 2026 interest income of $4.26M is the highest of the 8 companies compared; the peer median is $21K.
  • Its year-over-year change of +129.4% is the highest of 5, against a peer median of -33.3%.
  • Over three fiscal years its annual growth of +268.2% compares with a peer median of +15.8%.
IKT Competitors Peer median
Interest Income for IKT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IKTInhibikase Therapeutics, Inc.LTM Mar 2026$4.26M +129.4%+268.2%—
SRZNSurrozen, Inc.LTM Mar 2026$3.64M +126.7%+57.0%48.5%
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$134.35K -26.6%-25.3%—
TTRXTurn Therapeutics Inc.LTM Mar 2026$74.1K ———
AGENAgenus Inc.LTM Mar 2026$21K ——0.0%
ENTXEntera Bio Ltd.LTM Mar 2026$12K -40.0%——
CGTXCognition Therapeutics, Inc.LTM Mar 2026$0 ———
EXOZeXoZymes, Inc.LTM Mar 2026-$80.59K -185.5%——
Peer median (excluding IKT) $21K-33.3%+15.8%24.3%

Competitors are the stored peer set for IKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.1M123.44K260.5K00
Cost of Revenue11.36M6.72K13.62M26.27K0
Gross Profit(8.26M)116.72K(13.36M)(26.27K)0
Gross Margin-266.4%94.6%-5127.8%——
Research & Development11.36M12.03M13.62M17.21M29.79M
Selling, General & Admin06.21M6.73M11.38M23.56M
Operating Expenses6.51M18.25M6.73M28.56M51.97M
Depreciation & Amortization14.77M6.72K177.4K26.27K60.5K
EBITDA0(18.05M)(18.85M)(27.49M)(53.29M)
EBITDA Margin0.0%-14620.4%-7236.7%——
Operating Income(14.77M)(18.13M)(20.09M)(28.59M)(51.97M)
Operating Margin-476.2%-14686.2%-7712.0%——
Interest Income19.92K74.45K1.06M1.07M3.72M
Interest Expense19.92K74.45K000
Other Income / Expenses(19.92K)74.45K1.06M1.07M3.72M
Income Before Tax(14.79M)(18.05M)(19.03M)(27.52M)(48.26M)
Pre-Tax Margin-476.9%-14625.9%-7304.8%——
Income Tax Expense00000
Net Income(14.79M)(18.05M)(19.03M)(27.52M)(48.26M)
Net Margin-476.9%-14625.9%-7304.8%——
EPS (Basic)(4.88)(4.26)(3.57)(1.16)(0.49)
EPS (Diluted)(4.88)(4.26)(3.57)(1.16)(0.49)
Weighted Avg Shares3.03M4.2M5.33M69.36M98.31M
Weighted Avg Shares (Diluted)3.03M4.2M5.33M69.36M98.31M

Inhibikase Therapeutics, Inc.

NASDAQ:IKT

Intrinsic Alpha fair value

Locked

Current Price

$1.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.